I felt fine, but my Whoop data told a different story. Paying attention led to early detection and a successful treatment.

Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with ...

Dr. Sowmya Lakshminarayanan, or “Dr. Lak,” a neurologist and stroke expert at Novant Health, says that holiday stress, ...

The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...

Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt™ PFA System to treat patients battling atrial fibrillation (AFib). Abbott will soon begin ...

Boston Scientific ($BSX) announced an update on their ongoing clinical study. Study OverviewThis global Boston Scientific trial, officially titled ...

Johnson & Johnson MedTech today announced its sponsorship of a new PFA data collection platform from the Heart Rhythm Society ...

After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

Background Despite anticoagulation, patients with atrial fibrillation (AF) experience persistent elevated cardiovascular risk ...

Lab-grown hearts with immune cells develop atrial fibrillation after chronic inflammation, offering a new way to test ...

Coffee and the caffeine in it were long-considered a risk for patients with certain heart conditions. But a recent study ...